Coverage

5-Jan-2022

“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.
Read More

23-Nov-2021

Graham Kelly, CEO and Managing Director of Noxopharm, is passionate about mentoring young scientists.

Read More

28-Sep-2021

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US patent office has allowed claims relating to the use of a combination of its Veyonda and radiotherapy, including external beam radiotherapy (EBRT), with the purpose of generating abscopal responses in patients with metastatic prostate cancer.

Read more here

28-Sep-2021

“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.

Read here

2-Jul-2021

BiotechDispatch: Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US FDA has granted Investigational New Drug (IND) approval to the DARRT-2 study.

Read More here

2-Jul-2021

Proactive: Noxopharm Ltd (ASX:NOX) is set for a very busy six months ahead with news flow expected from its Veyonda® immune-oncology drug that works with the body’s defence mechanisms to fight cancer cells. 

Read More here

11-May-2021

Outsourcing-Pharma: Clinical study shows drug has COVID-19 treatment potential. CEO Dr. Graham Kelly discusses the history of Veyonda, details of the NOXCOVID study and next steps with Jenni Spinner, editor.

Read More here